High-dose-rate brachytherapy in a large squamous cell carcinoma of the hand

Fabrini, Maria Grazia; Perrone, F.; Liguoro, M. de; Cionini, L.

doi:10.1016/j.brachy.2008.04.004

Cited by 18 publications

(9 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tormo et al [10] also showed good toxicity results in patients treated in 6 or 7 fractions. Although most brachytherapy treatment schemas in the literature use 8 to 12 fractions [35,36,37,38,39,40], the fractionation used in this study does not result in a higher toxicity or a poorer cosmesis in comparison with a more fractionated treatment. Thus, in an elderly population, a comfortable schema that facilitates compliance is preferred.…”

Section: Discussionmentioning

confidence: 93%

Electronic brachytherapy for superficial and nodular basal cell carcinoma: a report of two prospective pilot trials using different doses

Ballester‐Sánchez¹,

Pons-Llanas

Candela-Juan

et al. 2016

jcb

View full text Add to dashboard Cite

Purpose: Basal cell carcinoma (BCC) is a very common cancer in the Caucasian population. Treatment aims to eradicate the tumor with the lowest possible functional and aesthetic impact. Electronic brachytherapy (EBT) is a treatment technique currently emerging. This study aims to show the outcomes of two consecutive prospective pilot clinical trials using different radiation doses of EBT with Esteya ® EB system for the treatment of superficial and nodular basal cell carcinoma.Material and methods: Two prospective, single-center, non-randomized, pilot studies were conducted. Twenty patients were treated in each study with different doses. The first group (1) was treated with 36.6 Gy in 6 fractions of 6.1 Gy, and the second group (2) with 42 Gy in 6 fractions of 7 Gy. Cure rate, acute toxicity, and late toxicity related to cosmesis were analyzed in the two treatment groups.Results: In group 1, a complete response in 90% of cases was observed at the first year of follow-up, whereas in group 2, the complete response was 95%. The differences with reference to acute toxicity and the cosmetic results between the two treatment groups were not statistically significant.Conclusions: Our initial experience with Esteya ® EB system to treat superficial and nodular BCC shows that a dose of 36.6 Gy and 42 Gy delivered in 6 fraction of 7 Gy achieves a 90% and 95% clinical cure rate at 1 year, respectively. Both groups had a tolerable toxicity and a very good cosmesis. The role of EBT in the treatment of BCC is still to be defined. It will probably become an established option for selected patients in the near future.

show abstract

Section: Discussionmentioning

confidence: 93%

Electronic brachytherapy for superficial and nodular basal cell carcinoma: a report of two prospective pilot trials using different doses

Ballester‐Sánchez¹,

Pons-Llanas

Candela-Juan

et al. 2016

jcb

View full text Add to dashboard Cite

show abstract

“…The development of new devices for small skin tumor treatment and the introduction of commercial electronic BT have attracted considerable interest for BT as a skin cancer treatment. Despite the new technologies available, few studies have focused on the treatment of NMSC with HDR-BT and hypofractionated regimes seems to be a valid option for the treatment of NMSC with very good local control, toxicity, and cosmetic result [19, 20, 21, 22, 23, 24, 25, 26, 32, 33, 34, 35, 36, 37, 43, 44]. In 1999, Köhler-Brock et al .…”

Section: Discussionmentioning

confidence: 99%

Non-melanoma skin cancer treated with high-dose-rate brachytherapy: a review of literature

Delishaj¹,

Rembielak²,

Manfredi³

et al. 2016

jcb

Self Cite

View full text Add to dashboard Cite

PurposeThe incidence of non-melanoma skin cancer (NMSC) has been increasing over the past 30 years. There are different treatment options and surgical excision is the most frequent treatment due to its low rates of recurrence. Radiotherapy is an effective alternative of surgery, and brachytherapy (BT) might be a better therapeutic option due to high radiation dose concentration to the tumor with rapid dose fall-off resulting in normal tissues sparing. The aim of this review was to evaluate the local control, toxicity, and cosmetic outcomes in NMSC treated with high-dose-rate BT (HDR-BT).Material and methodsIn May 2016, a systematic search of bibliographic database of PubMed, Web of Science, Scopus, and Cochrane Library with a combination of key words of “skin cancer”, “high dose rate brachytherapy”, “squamous cell carcinoma”, “basal cell carcinoma”, and “non melanoma skin cancer“ was performed. In this systematic review, we included randomized trials, non-randomized trials, prospective and retrospective studies in patients affected by NMSC treated with HDR-BT.ResultsOur searches generated a total of 85 results, and through a process of screening, 10 publications were selected for the review. Brachytherapy was well tolerated with acceptable toxicity and high local control rates (median: 97%). Cosmetic outcome was reported in seven study and consisted in an excellent and good cosmetic results in 94.8% of cases.ConclusionsBased on the review data, we can conclude that the treatment of NMSC with HDR-BT is effective with excellent and good cosmetics results, even in elderly patients. The hypofractionated course appears effective with very good local disease control. More data with large-scale randomized controlled trials are needed to assess the efficacy and safety of brachytherapy.

show abstract

“…[6][7][8] There has been increased interest in the use of customized intraoral mold HDR brachytherapy for oral malignancies. [9][10][11][12] This provides an additional option for patients with superficial oral cavity cancers that can be used as monotherapy or boost.…”

Section: Discussionmentioning

confidence: 99%

Use of customized intraoral mold high-dose-rate brachytherapy in the treatment of oral cavity cancer in an elderly patient

Wong

Cirino

Ladd

et al. 2015

Practical Radiation Oncology

View full text Add to dashboard Cite

High-dose-rate brachytherapy in a large squamous cell carcinoma of the hand

Cited by 18 publications

References 11 publications

Electronic brachytherapy for superficial and nodular basal cell carcinoma: a report of two prospective pilot trials using different doses

Electronic brachytherapy for superficial and nodular basal cell carcinoma: a report of two prospective pilot trials using different doses

Non-melanoma skin cancer treated with high-dose-rate brachytherapy: a review of literature

Use of customized intraoral mold high-dose-rate brachytherapy in the treatment of oral cavity cancer in an elderly patient

Contact Info

Product

Resources

About